CTA Testimony at first-ever FDA Public Meeting on Nanotechnology

October 10, 2006

At the Food and Drug Administration’s first-ever Public Meeting on Nanotechnology, CTA Staff Attorney George Kimbrell presented an outline of oversight and regulatory actions that the FDA should take to address the wave of nanomaterials in consumer products, particularly sunscreens, cosmetics, and other personal care products.

CTA recommended that three areas be given highest priority: Manufacturing worker and workplace safety; Nanomaterial consumer products and human health; and Environmental Impacts from nanomaterials.


Leave a Reply